Prognosis

AI Data Management Market worth $70.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, January 17, 2024
Cloud, Classification, Natural language processing, Research, SAS Institute, API, SAP, Prognosis, Algorithm, Microsoft Power BI, AWS, Data analysis, Data, Platform, General Data Protection Regulation, Data management, GDPR, Deployment, Environment, TIBCO Software, HPE, Image, Organization, Arctium, Artificial intelligence, Software as a service, IBM, Computer vision, Synthetic media, Trust, NLP, Microsoft, ThoughtSpot, Clinical trial, Comprehension, Medical device

Cloud services in AI data management offer flexibility, enabling businesses to scale resources up or down based on demand, optimizing costs.

Key Points: 
  • Cloud services in AI data management offer flexibility, enabling businesses to scale resources up or down based on demand, optimizing costs.
  • AI data management in healthcare & life sciences sector involves the comprehensive handling of vast amounts of patient data, genomic information, clinical trial results, and other healthcare-related data.
  • AI Data Management Market Advantages:
    Regular operations like data cleansing, normalisation, and classification are automated by AI in data management, increasing operational efficiency and lowering manual labour.
  • By upholding standard procedures for data processing, guaranteeing regulatory compliance, and enforcing data policies, AI-based data management systems improve data governance.

Powered by Its Industry-Leading Comprehensive Multi-Modal Database, Caris Life Sciences to Showcase Research at ASCO Gastrointestinal Cancers Symposium 2024

Retrieved on: 
Wednesday, January 17, 2024
Panitumumab, MSI, NGS, Patient, EGFR, Research, Cancer, MD, CTX, ASCO, Diagnosis, Cetuximab, CCA, AI, Society, NCI, Prognosis, TMB, FGFR2, Immunotherapy, FACP, Mutation, MBA, APC, Biomarker, CRC, POA, Abstract, GI, Medicine, Prevalence

IRVING, Texas, Jan. 17, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 11 studies across six solid tumor types at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco. The findings demonstrate the power of Caris' comprehensive multi-modal database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.  

Key Points: 
  • "We are proud to again present a wide array of precision oncology research at this year's ASCO GI.
  • Strikingly, patients with early-onset CCA experience better outcomes from immunotherapy even though immune-oncology-relevant markers like MSI and TMB favors average-onset CCA.
  • Two posters use EGFRi-treated CRC samples from the Caris multi-modal database to explore two promising possibilities: APC mutation status and CTX sensitivity score (CTX-S).
  • The POA includes 90 cancer centers, academic institutions, research consortia and healthcare systems, including 42 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Retrieved on: 
Tuesday, January 9, 2024
Myocarditis, Patient, European, Therapy, Research, Viral disease, Survival, Facial muscles, Fatigue, ARCHER, Heart failure, Freedom, Lightheadedness, Prognosis, Rest, Arrhythmia, Risk, Cancer, TSX, Arthralgia, Disease, Safety, Fever, Genetically modified bacteria, FDA, Inflammation, Biomarker, Marketing, Messenger, Clinical trial, Headache, Chest pain, CRDL, Pharmaceutical industry

Results from the ARCHER trial will assist in further understanding the therapeutic potential of CardiolRx™ and will complement the important clinical data from our ongoing MAvERIC-Pilot Phase II study in patients presenting with recurrent pericarditis."

Key Points: 
  • Results from the ARCHER trial will assist in further understanding the therapeutic potential of CardiolRx™ and will complement the important clinical data from our ongoing MAvERIC-Pilot Phase II study in patients presenting with recurrent pericarditis."
  • The ARCHER trial has been designed in collaboration with an independent steering committee comprising distinguished thought leaders in heart failure and myocarditis from international centers of excellence.
  • The trial is expected to enroll 100 patients at pre-eminent cardiovascular research centers in North America, France, Brazil, and Israel.
  • Orphan drug designation programs were established to provide life sciences companies with incentives to develop new therapies for rare diseases.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024
Woman, Weill Cornell Medicine, Research, Breast cancer screening, Share repurchase, Exemestane, University, Neoadjuvant therapy, Prognosis, Cancer, Breast, Risk, Breast Cancer Research Foundation, Cell death, University of California, Mastectomy, Ductal carcinoma, Diagnosis, Nature Portfolio, Growth, Silicon, Quantum Leap, Therapy, Neoplasm, BCRF, Seminal vesicles, Breast cancer, Disease, Patient, Lymph, Apoptosis, Radiation, Letter, Recurrence, TNBC, Phenotype, DCIS, PKC, Partnership, Mayo Clinic, Plasma, Triple-negative breast cancer, AKT, Springer Nature, FDA, Biomarker, PCR, Phosphorylation, Medical imaging

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer's Dementia

Retrieved on: 
Friday, January 12, 2024
Patient, MRI, JPMorgan Chase, SAN, Prognosis, Risk, Anxiety, De novo, Myenteric plexus, FDA, Montreal Cognitive Assessment, Amnesia, Psychological abuse, Diagnosis, Physician

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Today marks a turning point in the battle against Alzheimer's disease as Darmiyan, Inc., a leading company in brain health innovation announces the FDA's approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in brain health and opens the door to untapped market potential in brain disease diagnosis and management.

Key Points: 
  • Utilizing cutting-edge image processing and medical AI, BrainSee establishes a new standard for predicting progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia.
  • This approval marks a pivotal advancement in brain health and opens the door to untapped market potential in brain disease diagnosis and management.
  • BrainSee addresses a critical unmet need for over 10 million Americans and over 100 million patients worldwide grappling with aMCI.
  • It stands out for its prognostic accuracy, patient convenience, same-day test results and seamless integration into the clinical workflow.

Introduction of Breast Imaging Legislation Will Benefit Thousands of Virginians

Retrieved on: 
Tuesday, January 9, 2024
Woman, Patient, Legislation, MRI, Health, HB, Google Images, Breast cancer, Map, Cancer, Prognosis, Disease, Breast MRI, Magnetic resonance imaging, Biopsy, Diagnosis, Medical imaging

RICHMOND, Va., Jan. 9, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, commends Delegate Shelly Simonds (D-Newport News) for working with Komen to eliminate financial barriers to earlier breast cancer detection by ensuring that everyone has equitable access to diagnostic and supplemental breast imaging.

Key Points: 
  • In Virginia, 7,810 women were diagnosed with breast cancer in 2023 and 1,150 died of the disease.
  • HB 230 , introduced by Delegate Simonds, eliminates the patient out-of-pocket costs for medically necessary diagnostic and supplemental breast imaging including MRIs, ultrasounds and diagnostic mammograms.
  • An estimated 12% of individuals are called back for additional imaging after an abnormal screening mammogram and require diagnostic imaging.
  • This diagnostic or supplemental imaging is often crucial for individuals previously diagnosed with breast cancer or those considered high-risk.

Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types

Retrieved on: 
Monday, January 8, 2024
Radiology, Health Technology, Health, Oncology, Prognosis, FDA, Lung, Doctor of Philosophy, Cancer, Conceptual model, Marie Cassidy, Science, Behavior, Microsoft Research, Preprint, AI1, Library, Gastrointestinal tract, Genomics, DIGITAL, Pathology, ArXiv, Patient, Diagnosis, Rudolf Virchow, Skin, Senior, Medical imaging

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade.

Key Points: 
  • Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade.
  • With data derived from over 4 million digitized slides, Paige's innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.
  • The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI1.
  • “We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige.

miRNA Sequencing And Assay Market Research Report 2023: Global Size, Share & Trends Analysis and Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Genetics, Health, Oncology, RNA, Partnership, Sepsis, Prognosis, Antibody, Research, Workflow, Plasma, Breast, Ion semiconductor sequencing, MicroRNA, Cancer, USD, Mutation, COVID-19, Nervous system, Biomarker, Coronavirus, PerkinElmer, Library, Growth, Patient, Diagnosis, Application, Qiagen, Fine chemical

The "miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global miRNA sequencing and assay market size is expected to reach USD 823.5 Million by 2030, registering a CAGR of 13.3% from 2023 to 2030.
  • Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders.
  • For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, European Commission, Food, HRR, Risk, Movement, Prognosis, PFE, Confidence interval, Disease, Prostate cancer, Doctor of Philosophy, Civil service commission, Cancer, University, PARP, Death, Clinical Cancer Research, University of Glasgow, ADP, Talazoparib, Patient, Safety, Medicine, Inc., Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
  • With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations.
  • “The European Commission’s approval of talazoparib in combination with enzalutamide offers a meaningful advancement for the treatment of patients with metastatic castration-resistant prostate cancer, the most advanced and aggressive stage of the disease.”
    “After years of fighting prostate cancer, it can be devastating for a patient to learn that their cancer has stopped responding to testosterone-lowering treatments.
  • At this stage of the disease, the prognosis is generally poor,” said Erik Briers, MS, PhD, Vice Chairman, Europa UOMO, a European advocacy movement for people with prostate cancer.